# The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension

> **NCT01360710** · PHASE4 · UNKNOWN · sponsor: **Baker Heart and Diabetes Institute** · enrollment: 100 (estimated)

## Conditions studied

- Abdominal Obesity
- Hypertension

## Interventions

- **DRUG:** Moxonidine
- **DRUG:** Irbesartan

## Key facts

- **NCT ID:** NCT01360710
- **Lead sponsor:** Baker Heart and Diabetes Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-01
- **Primary completion:** 2014-01
- **Final completion:** —
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2012-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01360710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01360710, "The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01360710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*